These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 9516091

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.
    N Engl J Med; 1999 Jan 07; 340(1):23-30. PubMed ID: 9878641
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct 07; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.
    Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G.
    Pediatr Pulmonol; 2011 Mar 07; 46(3):230-8. PubMed ID: 20963831
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL.
    J Infect Dis; 1999 May 07; 179(5):1190-6. PubMed ID: 10191222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Microbiological and immunologic considerations with aerosolized drug delivery.
    LiPuma JJ.
    Chest; 2001 Sep 07; 120(3 Suppl):118S-123S. PubMed ID: 11555566
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M, Smyth A, Geller DE.
    Respir Med; 2011 Dec 07; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.